急性髓系白血病患者接受非血缘供者造血干细胞移植后,移植后环磷酰胺与传统抗移植物抗宿主病预防方案的复发率相当:欧洲血液与骨髓移植学会急性白血病工作组研究
该研究比较了7049例缓解期急性髓系白血病患者接受非血缘造血干细胞移植后,采用移植后环磷酰胺(PTCy)与未采用PTCy的移植物抗宿主病(GVHD)预防方案的复发率。PTCy组707例,无PTCy组6342例。结果显示两组复发率无显著差异(HR 1.11,95%CI 0.9-1.37,p=0.31),但PTCy组GVHD发生率和非复发死亡率显著更低,无GVHD无复发生存率更高。
要点
- PTCy组与无PTCy组复发率无显著差异,HR 1.11(95%CI 0.9-1.37,p=0.31)。
- PTCy组急性GVHD II-IV度和III-IV度发生率显著低于无PTCy组。
- PTCy组非复发死亡率显著更低,无GVHD无复发生存率显著更高。
核心结论
- 在缓解期急性髓系白血病患者接受非血缘供者造血干细胞移植中,PTCy组与无PTCy组的复发率、总生存率和无白血病生存率相当,PTCy组GVHD发生率和非复发死亡率显著更低,无GVHD无复发生存率显著更高。
研究设计与样本
- 欧洲血液与骨髓移植学会急性白血病工作组开展的研究,比较7049例缓解期急性髓系白血病患者接受非血缘造血干细胞移植后,采用PTCy(707例)与未采用PTCy(6342例)GVHD预防方案的结局。
主要发现
- PTCy组患者更年轻,52.7岁 vs 无PTCy组56.6岁(p<0.001)。
- PTCy组9/10供者比例更高,33.8% vs 无PTCy组16.4%(p<0.001);清髓性预处理比例更高,61.7% vs 无PTCy组50.2%(p<0.001)。
- 无PTCy组87.7%患者接受体内T细胞去除。
- PTCy组中性粒细胞和血小板植入率低于无PTCy组,分别为93.8%和80.9% vs 97.6%和92.6%(p<0.001)。
- PTCy组复发率与无PTCy组无显著差异,HR 1.11(95%CI 0.9-1.37,p=0.31)。
关键数值与推荐
- 急性GVHD II-IV度:PTCy组 vs 无PTCy组 HR 0.74(95%CI 0.59-0.92,p=0.007)。
- 急性GVHD III-IV度:PTCy组 vs 无PTCy组 HR 0.56(95%CI 0.38-0.83,p=0.004)。
- 慢性GVHD总数:PTCy组 vs 无PTCy组 HR 0.5(95%CI 0.41-0.62,p<0.001);广泛型慢性GVHD:HR 0.31(95%CI 0.22-0.42,p<0.001)。
- 非复发死亡率:PTCy组 vs 无PTCy组 HR 0.67(95%CI 0.5-0.91,p=0.007)。
- 无GVHD无复发生存率:PTCy组 vs 无PTCy组 HR 0.69(95%CI 0.59-0.81,p=0.001)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
We compared relapse incidence (RI) post-unrelated transplantation with post-transplant cyclophosphamide (PTCy) versus no PTCy graft-versus-host disease (GVHD) prophylaxis, in 7049 acute myeloid leukemia (AML) patients in remission, 707 with PTCy, and 6342 without (No PTCy). The patients in the PTCy group were younger, 52.7 versus 56.6 years (p < .001). There were more 9/10 donors in the PTCy group, 33.8% versus 16.4% (p < .001), and more received myeloablative conditioning, 61.7% versus 50.2% (p < .001). In the No PTCy group, 87.7% of patients received in vivo T-cell depletion. Neutrophil and platelet engraftment were lower in the PTCy versus No PTCy group, 93.8% and 80.9% versus 97.6% and 92.6% (p < .001). RI was not significantly different in the PTCy versus the No PTCy group, hazard ratio (HR) of 1.11 (95% confidence interval [CI] 0.9-1.37) (p = .31). Acute GVHD grades II-IV and III-IV, were significantly lower in the PTCy versus the No PTCy group, HR of 0.74 (95% CI 0.59-0.92, p = .007) and HR = 0.56 (95% CI 0.38-0.83, p = .004), as were total and extensive chronic GVHD, HRs of 0.5 (95% CI 0.41-0.62, p < .001) and HR = 0.31 (95% CI 0.22-0.42, p < .001). Non-relapse mortality (NRM) was significantly lower with PTCy versus the No PTCy group, HR of 0.67 (95% CI 0.5-0.91, p = .007). GVHD-free, relapse-free survival (GRFS) was higher in the PTCy versus the No PTCy group, HR of 0.69 (95% CI 0.59-0.81, p = .001). Leukemia-free survival (LFS) and overall survival (OS) did not differ between the groups. In summary, we observed comparable RI, OS, and LFS, significantly lower incidences of GVHD and NRM, and significantly higher GRFS in AML patients undergoing unrelated donor-hematopoietic stem cell transplantation with PTCy versus No PTCy GVHD prophylaxis.
引用
- Nagler A, Ngoya M, Galimard JE, et al. Comparable relapse incidence after unrelated allogeneic stem cell transplantation with post-transplant cyclophosphamide versus conventional anti-graft versus host disease prophylaxis in patients with acute myeloid leukemia: A study on behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Am J Hematol. 2024. PMID: 38856236. doi:10.1002/ajh.27383
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。